Poor medication adherence presents a significant barrier to successful treatment and recovery in patients with serious mental illness and can negatively impact health outcomes and health care costs. While various clinical tools and approaches exist for the assessment and enhancement of medication adherence, many have yet to be widely adopted into psychiatric practice. Please join Hayden Bosworth, PhD, and Michael Measom, MD, as they discuss the importance of medication adherence for patients with serious mental illness, review methods which clinicians can utilize to assess medication adherence in their patients, and consider some tools and approaches clinicians can implement to promote and optimize medication adherence.

Speakers are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. and will be compensated for participation in this event.

JOIN US FOR A FREE VIRTUAL FORUM:

Tools To Assess & Address Medication Adherence In Patients With Serious Mental Illness

WEDNESDAY DECEMBER 13, 2017
12PM ET | 9AM PT

Featuring:

Hayden Bosworth, PhD
Hayden Bosworth, PhD, is a Health Services Researcher; Professor of Population Health Sciences, Medicine, Psychiatry, & Nursing; and Associate Chair of Education for the Department of Population Health Sciences at Duke University Medical Center. He also serves as the Associate Director of the Center for Health Service Research in Primary Care Center of Innovation (COIN) at the Durham VAMC.

Dr. Bosworth received his PhD in human development and family studies from The Pennsylvania State University. He completed his postdoctoral fellowship at the Duke University Medical Center in Durham, North Carolina.

Michael Measom, MD
Michael Measom, MD, is the Medical Director of the Assertive Community Treatment (ACT) Team at Volunteers of America, and Medical Director of New Roads Behavioral Health. He is board certified in general psychiatry, addiction psychiatry, and addiction medicine.

Dr. Measom received his MD from the University of Utah. He completed his residency in psychiatry at the University of Wisconsin-Madison and a Fellowship in addiction psychiatry at the Medical University of South Carolina.

Joe Cirrincione, PharmD, MBA, Managed Market Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc., will be the moderator of this event.

Additional Resources On PsychU:

Treatment Of Schizophrenia: Focus On Psychopharmacology & Adherence
Virtual Forum Summary

• Current & Remitted Depression & Anxiety Disorders As Risk Factors For Medication Nonadherence
• Understanding & Addressing Medication Adherence In Psychiatry

PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC - committed supporters of the mental health treatment community. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice or professional diagnosis. Health care professionals should use their independent medical judgment when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and/or Lundbeck, LLC.

© 2017 Otsuka Pharmaceutical Development & Commercialization, Inc.

REGISTER & ACCESS THESE RESOURCES TODAY AT: www.PsychU.org